
Tetanus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Tetanus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Drugs In Development, 2022, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.
Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 6, 8, 2, 14, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tetanus – Drugs In Development, 2022, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.
Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tetanus – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 7, 6, 8, 2, 14, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
77 Pages
- Introduction
- Global Markets Direct Report Coverage
- Tetanus – Overview
- Tetanus – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tetanus – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tetanus – Companies Involved in Therapeutics Development
- AIM Vaccine Co Ltd
- Beijing Minhai Biotechnology Co Ltd
- Beijing Tiantan Biological Products Co Ltd
- Biken Co Ltd
- Biological E Ltd
- BioNet-Asia Co Ltd
- Boryung Pharmaceutical Co Ltd
- CanSino Biologics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Kanghua Biological Products Co Ltd
- Chengdu Olymvax Biopharmaceuticals Inc
- Chongqing Zhifei Biological Products Co Ltd
- GC Biopharma Corp
- KM Biologics Co Ltd
- LG Chem Ltd
- Novo Medi Sciences Pvt Ltd
- NTxBio LLC
- Panacea Biotec Ltd
- Sanofi
- Seasons Healthcare Ltd
- Serum Institute of India Pvt Ltd
- Shantha Biotechnics Pvt Ltd
- Sichuan ZehaTimes Pharmaceutical Co Ltd
- Stablepharma Ltd
- Suzhou Weichao Biotechnology Co Ltd
- VaxForm LLC
- Yunnan Watson Biotechnology Co Ltd
- Yuxi Jiuzhou Biological Technology Co Ltd
- Zhuhai Trinomab Biotechnology Co Ltd
- Zydus Lifesciences Ltd
- Tetanus – Drug Profiles
- (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine – Drug Profile
- (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine – Drug Profile
- (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine – Drug Profile
- (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine – Drug Profile
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine – Drug Profile
- (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine – Drug Profile
- (diphtheria + haemophilus influenzae [serotype B] + pertussis (whole cell) + tetanus) vaccine – Drug Profile
- (diphtheria + pertussis (acellular) + tetanus) vaccine – Drug Profile
- (diphtheria + pertussis (acellular) + tetanus) vaccine 1 – Drug Profile
- (diphtheria + pertussis (acellular) + tetanus) vaccine 2 – Drug Profile
- (diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine – Drug Profile
- (diphtheria + pertussis (whole cell) + tetanus) vaccine – Drug Profile
- (diphtheria + pertussis + poliomyelitis + tetanus) vaccine – Drug Profile
- (diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine – Drug Profile
- (diphtheria + pertussis + tetanus) vaccine – Drug Profile
- (diphtheria + tetanus + pertussis (acellular) + haemophilus influenzae [serotype B]) vaccine – Drug Profile
- (diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine – Drug Profile
- (diphtheria + tetanus + pertussis (acellular)) vaccine 1 – Drug Profile
- (diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine – Drug Profile
- (diphtheria + tetanus) vaccine – Drug Profile
- Adacel plus – Drug Profile
- Antibody for Tetanus – Drug Profile
- B-1004 – Drug Profile
- BK-1310 – Drug Profile
- DTcP vaccine – Drug Profile
- GC-3111A – Drug Profile
- KD-370 – Drug Profile
- LBVD – Drug Profile
- LR-20062 – Drug Profile
- NTXV-01 – Drug Profile
- tetanus vaccine – Drug Profile
- TNM-002 – Drug Profile
- Tetanus – Dormant Projects
- Tetanus – Discontinued Products
- Tetanus – Product Development Milestones
- Featured News & Press Releases
- Apr 26, 2022: KM Biologics files DTaP-IPV-Hib vaccine in Japan
- Apr 12, 2022: Pertussis, Diphtheria, Tetanus, Polio, Hib vaccine filed in Japan: BIKEN/Mitsubishi
- Apr 11, 2022: Marketing authorization application of pertussis, diphtheria, tetanus, inactivated polio and Hib combined vaccine (BK1310/MT-2355)
- Mar 11, 2019: LG Chem gets $33.4 mil. from Gates Foundation for vaccine development
- Aug 02, 2016: CanSino submits a clinical trial application for the component DTP diptheria tetanus pertussis combo vaccine (adults, teenagers and children above 6 years Old)
- Sep 01, 2015: Commercialisation of a world changing invention for the stabilisation and delivery of vaccines
- Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Tetanus, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Universities/Institutes, 2022
- Table 4: Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022 (Contd..1)
- Table 6: Products under Development by Universities/Institutes, 2022
- Table 7: Number of Products by Stage and Target, 2022
- Table 8: Number of Products by Stage and Mechanism of Action, 2022
- Table 9: Number of Products by Stage and Route of Administration, 2022
- Table 10: Number of Products by Stage and Molecule Type, 2022
- Table 11: Tetanus – Pipeline by AIM Vaccine Co Ltd, 2022
- Table 12: Tetanus – Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Table 13: Tetanus – Pipeline by Beijing Tiantan Biological Products Co Ltd, 2022
- Table 14: Tetanus – Pipeline by Biken Co Ltd, 2022
- Table 15: Tetanus – Pipeline by Biological E Ltd, 2022
- Table 16: Tetanus – Pipeline by BioNet-Asia Co Ltd, 2022
- Table 17: Tetanus – Pipeline by Boryung Pharmaceutical Co Ltd, 2022
- Table 18: Tetanus – Pipeline by CanSino Biologics Inc, 2022
- Table 19: Tetanus – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
- Table 20: Tetanus – Pipeline by Chengdu Kanghua Biological Products Co Ltd, 2022
- Table 21: Tetanus – Pipeline by Chengdu Olymvax Biopharmaceuticals Inc, 2022
- Table 22: Tetanus – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
- Table 23: Tetanus – Pipeline by GC Biopharma Corp, 2022
- Table 24: Tetanus – Pipeline by KM Biologics Co Ltd, 2022
- Table 25: Tetanus – Pipeline by LG Chem Ltd, 2022
- Table 26: Tetanus – Pipeline by Novo Medi Sciences Pvt Ltd, 2022
- Table 27: Tetanus – Pipeline by NTxBio LLC, 2022
- Table 28: Tetanus – Pipeline by Panacea Biotec Ltd, 2022
- Table 29: Tetanus – Pipeline by Sanofi, 2022
- Table 30: Tetanus – Pipeline by Seasons Healthcare Ltd, 2022
- Table 31: Tetanus – Pipeline by Serum Institute of India Pvt Ltd, 2022
- Table 32: Tetanus – Pipeline by Shantha Biotechnics Pvt Ltd, 2022
- Table 33: Tetanus – Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, 2022
- Table 34: Tetanus – Pipeline by Stablepharma Ltd, 2022
- Table 35: Tetanus – Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022
- Table 36: Tetanus – Pipeline by VaxForm LLC, 2022
- Table 37: Tetanus – Pipeline by Yunnan Watson Biotechnology Co Ltd, 2022
- Table 38: Tetanus – Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, 2022
- Table 39: Tetanus – Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
- Table 40: Tetanus – Pipeline by Zydus Lifesciences Ltd, 2022
- Table 41: Tetanus – Dormant Projects, 2022
- Table 42: Tetanus – Dormant Projects, 2022 (Contd..1)
- Table 43: Tetanus – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Tetanus, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Targets, 2022
- Figure 5: Number of Products by Stage and Targets, 2022
- Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 7: Number of Products by Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.